Results 21 to 30 of about 38,525 (259)

ICD Outcome in Pediatric Cardiomyopathies

Journal of Cardiovascular Development and Disease, 2022
Background: Pediatric patients with cardiomyopathies are at risk of malignant arrhythmias and sudden cardiac death (SCD). An ICD may prevent SCD. The aim of this study was to evaluate ICD implantation outcomes, and to compare transvenous and subcutaneous
Massimo Stefano Silvetti, Ilaria Tamburri, Marta Campisi, Fabio Anselmo Saputo, Ilaria Cazzoli, Nicoletta Cantarutti, Marianna Cicenia, Rachele Adorisio, Anwar Baban, Lucilla Ravà, Fabrizio Drago   +10 more
doaj   +1 more source

The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy

Journal of Feline Medicine and Surgery, 2021
Practical relevance: Hypertrophic cardiomyopathy (HCM) is the most common form of feline cardiomyopathy observed clinically and may affect up to approximately 15% of the domestic cat population, primarily as a subclinical disease. Fortunately, severe HCM, leading to heart failure or arterial thromboembolism (ATE)
Kittleson, Mark D, Côté, Etienne
openaire   +3 more sources

Overview of Cardiomyopathies in Childhood

Frontiers in Pediatrics, 2021
Paediatric cardiomyopathies are a heterogenous group of rare disorders, characterised by mechanical and electrical abnormalities of the heart muscle. The overall annual incidence of childhood cardiomyopathies is estimated at about 1 per 100,000 children ...
Anika Rath, Robert Weintraub, Robert Weintraub, Robert Weintraub   +3 more
doaj   +1 more source

A green tea extract catechin EGCg: Therapeutic potential for pediatric cardiomyopathies

Pediatric Discovery, 2023
Cardiomyopathies comprise a group of disorders wherein the primary defect is in cardiac myocytes. The common forms of pediatric cardiomyopathies, classified according to their morphological and functional manifestations, include dilated cardiomyopathy ...
Junjun Quan, Dustin Gerber, Ang Li, Xupei Huang, Jie Tian   +4 more
doaj   +1 more source

Infiltrative Cardiomyopathies

Clinical Medicine Insights: Cardiology, 2015
Infiltrative cardiomyopathies can result from a wide spectrum of both inherited and acquired conditions with varying systemic manifestations. They portend an adverse prognosis, with only a few exceptions (ie, glycogen storage disease), where early ...
David Bejar, Paolo C. Colombo, Farhana Latif, Melana Yuzefpolskaya   +3 more
doaj   +2 more sources

Human-induced pluripotent stem cells in modeling inherited cardiomyopathies

Journal of the Practice of Cardiovascular Sciences, 2015
Our current understanding of molecular mechanisms of cardiomyopathies has been elucidated from genetic animal models. Induced pluripotent stem cells (iPSCs) can provide a platform to improve our understanding of familial cardiomyopathies diseases.
Subhoshree Ghose, Anju Sharma, Aishwarya Agarwal, Shantanu Sengupta   +3 more
doaj   +1 more source

Eclipsed Functional Mitral Regurgitation Destabilizing Hypertrophic Cardiomyopathy: An Unusual Case Treated With MitraClipNovel Teaching Points

CJC Open, 2021
MitraClip (Abbott Laboratories, Abbott Park, IL) is validated in high-risk patients with severe degenerative mitral regurgitation (MR); however, it is not well established for functional MR in hypertrophic cardiomyopathy (HCM).
Catherine Bourque, MD, Marina Dijos, MD, Lionel Leroux, MD, Louis Labrousse, MD, Alexandre Metras, MD, Matthieu Michaud, MD, Marie Hébert, MD, Patricia Réant, MD, Stéphane Lafitte, MD   +8 more
doaj   +1 more source

A very rare cause of pre‐capillary pulmonary hypertension: The PAMI syndrome

Pulmonary Circulation, 2023
We report the first known case of PAMI syndrome associated with pulmonary arterial hypertension (PAH) with a positive response to cyclophosphamide and pulmonary vasodilators. The patient's history began at 7 months with severe pancytopenia and fever.
Manuela Iseppi, Giulio Savonitto, Alberto Tommasini, Alessia Pin, Gianfranco Sinagra, Davide Stolfo   +5 more
doaj   +1 more source

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

Reviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani   +7 more
doaj   +1 more source